serosa positive gastric cancer
Conditions
Interventions
intraperitoneal and intravenous Paclitaxel plus TS-1
Sponsors
Intraperitoneal chemotherapy study group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (i) Histologically proven common gastric carcinoma (ii) Suspected serosa invasive gastric cancer (iii) There must be an absence of peritoneal metastasis or negative finding from peritoneal washing cytology confirmed by staging laparoscopy (iv) The patient must have clinically resectable gastric cancer (v) Tumor invasion of the esophagus must be less than 3 cm, (vi) Patients must be in the age range 20-75 years (vii) The Eastern Cooperative Oncology Group performance status must be 0 or 1 (viii) No previous therapy against GC should have been carried out, and no previous chemotherapy, CRT or radiotherapy (ix) No typical bleeding from GC and stenosis of gastro-intestinal tract should have occurred (x) Sufficient oral intake is required (xi) Written informed consent will be obtained from all patients (xii) Adequate organ functions are required
Exclusion criteria
Exclusion criteria: (i) The occurrence of simultaneous or metachronous (within 5 years) double cancers, with the exception of intramucosal tumor that is curable with local therapy (ii) A history of severe drug hypersensitivity (iii) The presence of active bacterial or fungal infection, and a body temperature over 38 temperature. (iv) Pregnancy or lactation in women of childbearing potential (v) Men who wish the partners pregnancy (vi) The presence of unstable angina, heart failure or a history of myocardial infarction within 6 months (vii) Patients requiring systemic steroid medication (viii) Patients requiring the administration of phenytoin or warfarin potassium (ix) The presence to peptic ulcer or bleeding (x) The presence of severe diarrhea (xi) The presence of antigen-positive serum HBs and/or antibody positive serum HVC (xii) The presence of uncontrollable intestinal paralysis, interstitial pneumonitis or ischemic heart disease (xiii) Patients determined to be inappropriate for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| percent completion of protocol treatment | — |
Countries
Japan
Contacts
Public ContactMotohiro Imano
Kinki University Faculty of Medicine Department of Surgery
Outcome results
None listed